 | Up a level |
Felip, E. and Cho, B. C. and Gutierrez, V and Alip, A. and Besse, B. and Lu, S. and Spira, A. I. and Girard, N. and Califano, R. and Gadgeel, S. M. and Yang, J. C-H. and Yamamoto, S. and Azuma, K. and Kim, Y. J. and Lee, K. -H. and Danchaivijitr, P. and Ferreira, C. G. and Cheng, Y. and Sendur, M. A. N. and Chang, G. -C. and Wang, C. -C. and Prabhash, K. and Shinno, Y. and Stroyakovskiy, D. and Paz-Ares, L. and Rodriguez-Cid, J. R. and Martin, C. and Campelo, M. R. G. and Hayashi, H. and Nguyen, D. and Tomasini, P. and Gottfried, M. and Dooms, C. and Passaro, A. and Schuler, M. and Gelatti, A. C. Z. and Owen, S. and Perdrizet, K. and Ou, S. -H. I. and Curtin, J. C. and Zhang, J. and Gormley, M. and Sun, T. and Panchal, A. and Ennis, M. and Fennema, E. and Bauml, J. M. and Daksh, M. and Sethi, S. and Lee, S. -H. (2024) Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Annals of Oncology, 35 (9). pp. 805-816. ISSN 0923-7534, DOI https://doi.org/10.1016/j.annonc.2024.05.541.
Passaro, A. and Wang, J. and Wang, Y. and Lee, S. -H. and Melosky, B. and Shih, J. -Y. and Wang, J. and Azuma, K. and Juan-Vidal, O. and Cobo, M. and Felip, E. and Girard, N. and Cortot, A. B. and Califano, R. and Cappuzzo, F. and Owen, S. and Popat, S. and Tan, J. -l. and Salinas, J. and Tomasini, P. and Gentzler, R. D. and William, W. N. and Reckamp, K. L. and Takahashi, T. and Ganguly, S. and Kowalski, D. M. and Bearz, A. and MacKean, M. and Barala, P. and Bourla, A. B. and Girvin, A. and Greger, J. and Millington, D. and Withelder, M. and Xie, J. and Sun, T. and Shah, S. and Diorio, B. and Knoblauch, R. E. and Bauml, J. M. and Campelo, R. G. and Cho, B. C. and Investigators, MARIPOSA-2 (2024) Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Annals of Oncology, 35 (1). ISSN 0923-7534, DOI https://doi.org/10.1016/j.annonc.2023.10.117.
